Included Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Included Health provides comprehensive health navigation and care delivery for employers, specializing in complex conditions, mental health, and LGBTQ+ healthcare needs.
About
Included Health is a digital health company formed through the 2021 merger of Grand Rounds Health and Doctor On Demand, creating a unified platform for health navigation and virtual care delivery for employer health plans. The company provides members with access to expert second opinions, specialist referrals, primary care, mental health services, and benefits navigation through a single integrated platform. Included Health has built specialized expertise in serving populations with complex care needs including members with serious diagnoses, those seeking LGBTQ+-affirming care, and employees navigating mental health challenges. The company raised over $300M and serves large self-insured employers as a comprehensive health benefit that supplements traditional insurance. The merger combined Grand Rounds' navigation and expert medical opinion capabilities with Doctor On Demand's virtual primary care and psychiatry platform, creating broader clinical coverage than either company offered independently. Included Health positions itself as a health equity platform that improves outcomes for all employees regardless of their health complexity, geographic location, or demographic characteristics.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.